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The Emerging Role of Ticagrelor in Acute Coronary Syndromes
Jennifer Bauer, fifth-year pharmacy student from St. Marys, Pa.; Brittany Dye, fourth-year pharmacy student from Tiro,
Ohio; Kimberly Baucher, fourth-year pharmacy student from Findlay, Ohio; Megan Keller, PharmD '11, community
pharmacy resident; David Bright, PharmD, BCACP, assistant professor of pharmacy practice; Karen L. Kier, BSPh '82, Ph.D.,
R.Ph., BCPS, BCACP, professor of clinical pharmacy, director of assessment
This knowledge-based activity is targeted for all phannacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UAN): 0048-0000-11-051-HO 1-P

Objectives:
After completion of this program, the reader should be able
to:
1. List the disease states associated with acute coronary
syndromes (ACS) and general treatment approaches.
2. Describe the rationale behind the development of new
antiplatelet drug therapies.
3. Explain the mechanisms of action of clopidogrel, prasugrel and ticagrelor.
4. List the advantages and disadvantages of treating ACS
with either clopidogrel, prasugrel or ticagrelor.
5. Describe the appropriate patient populations indicated
for each drug therapy.
Abstract
Antiplatelet therapy has become a mainstay in the treatment
of acute coronary syndromes (ACS). Until recently, options
were somewhat limited when it came to individualizing drug
selection. Plavix® (clopidogrel) has been successfully used
for many years but requires activation by CYP enzymes. Depending on an individual patient's genetic makeup, function
of these CYP enzymes may be altered, which may increase
the risk for clots. The recent approval of Effient® (prasugrel)
and Brilinta® (ticagrelor) has provided physicians and pharmacists with more options and may hopefully lead to improved clinical outcomes. Ticagrelor specifically exhibits
clinically different pharmacologic characteristics that require
twice daily dosing, but also allows for faster onset and offset,
as well as more predictable platelet inhibition as compared
to dopidogrel. Additional postmarketing surveillance and
treatment guidelines wm hopefully continue to guide appropriate selection of antiplatelet therapies.
Introduction
Acute coronary syndromes, which include unstable angina
(UA), non-ST elevated myocardial infarction (NSTEMl) and
ST elevated myocardial infarction (STEMI) are among the
leading causes of mortality today.1 Platelets play a key role in
atherothrombosis and may be a key contributor to ACs.2 As a
result, antiplatelet agents are commonly used as a preventive
measure, particularly after a patient has suffered from ACS.
Aspirin is often seen as the foundational antiplatelet agent.
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When Plavix® (clopidogrel) is combined with aspirin, the
additive antiplatelet effect has been shown to provide further
benefit. However, due to variability among patients in response level, as well as delayed onset, researchers are seeking to find new and better ways of implementing antiplatelet
therapy for patients with ACS. Effient® (prasugrel) and Brilinta® (ticagrelor) are two viable alternatives to clopidogrel in
the treatment of ACS. Ticagrelor specifically offers different
characteristics than clopidogrel and prasugrel and shows
promise as a part of the standard of care in ACS. The goal of
this paper is to review the use of existing antiplatelet therapies and to highlight clinically relevant studies and strategies
of care for ticagrelor.
Clopidogrel
Clopidogrel has been the standard of care for ACS for many
years. Clopidogrel is a prodrug that must undergo a two-step
metabolism in order to be converted to the active metabolite.
Peak levels of the active metabolite are observed approximately three to four hours after administration. Cytochrome
P450 (CYP450) enzymes, most notably CYP2C19, first convert clopidogrel to 2-oxo-clopidogrel, which is then hydrolyzed into the active metabolite responsible for irreversibly
blocking ADP P2Y 12 receptors on the platelet surface, therefore inhibiting platelet aggregation.1
As CYP2C19 is involved in both steps of the biotransformation of clopidogrel, the CYP2C19 genotype is a significant
contributing factor to response variability for clopidogrel.
Genetics and ethnicity may lead to changes in the CYP enzymes, potentially resulting in clopidogrel resistance.1
CYP2C19*1 is the wild-type, or common, allele while
CYP2C19*2, CYP2C19*3 and CYP2C19*17 are examples of
alternate alleles that may express reduced or increased enzymatic function. Alterations in CYP3A5 and ABCBl may also
affect clopidogrel metabolism.3 Based on the genetic variability of the biotransformation process, the FDA is recommending genetic testing for patients on clopidogrel due to the potential for clopidogrel to not function fully (clopidogrel nonresponsiveness ).2·4
Clopidogrel is used to reduce the rate of atherothrombotic
events in patients with UA, NSTEMI or STEMI. In patients
with STEMI who are managed medically, it can also reduce
the mortality rate. The typical dose of clopidogrel is 300 mg
as a loading dose followed by 75 mg every day accompanied
by 75-162 mg of aspirin every day for patients with UA,
NSTEMI or STEMI. In CYP2C19 poor metabolizers, a 600 mg
loading dose with 150 mg per day has been utilized. Clopidogrel is contraindicated in any patient with known hypersensitivity to clopidogrel or any component of the product, and
in any patient with active pathological bleeding such as GI
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and/or intracranial bleeding.s Clopidogrel is not recommended for use in patients with reduced CYP2Cl 9 function
due to the decreased activation of clopidogrel. Adverse reactions to clopidogrel include dermatologic rash or pruritus,
bruising, epistaxis and other bleeding that may be major or
minor. These reactions occur in less than 10 percent of patients taking clopidogrel.
The Clopidogrel in Unstable angina to prevent Recurrent
Events (CURE) study was a randomized, double-blind, placebo-controlled trial in patients presenting with non-ST segment elevated ACS.6.7 Patients were either placed in the
clopidogrel or placebo group. The clopidogrel group received
300 mg as a loading dose followed by a 75 mg maintenance
dose, while the placebo group received a matching placebo
dosing regimen. Both groups received aspirin 75-325 mg
daily as prescribed by the physician. Follow-up occurred at
three-month intervals and continued up to one year, with an
average duration of nine months. The primary outcome
measured was a composite of cardiovascular death, myocardial infarction and stroke. In order to measure safety, bleeding complications were measured. Clopidogrel lead to a significant reduction in the primary outcome. The researchers
also determined that the likelihood of benefit substantially
outweighs the risks oflife-threatening or major bleeding.
Prasugrel
Prasugrel also irreversibly blocks P2Y 12 receptors; however,
it is 10 times more potent than clopidogrel. Prasugrel is a
prodrug that is rapidly converted to an active metabolite via
a single-step process using CYP3A4 and CYP2B6.B Peak
plasma levels are reached approximately 30 minutes after
administration.9 Despite 70 percent of prasugrel being excreted renally, it does not require dosage adjustment for renal impairment.10 Prasugrel has a more consistent and potent inhibition of platelet aggregation than clopidogrel.
Therefore, prasugrel may be appropriate in a patient who
does not respond to clopidogrel. However, prasugrel has an
increased risk of bleeding, especially in patients with a history of stroke or patients over 75 years of age.
Prasugrel is recommended for use in patients who are being
managed with percutaneous coronary intervention (PCI) for
UA, NSTEMI or STEM! to reduce the rate of thrombotic cardiovascular events.a Patients with ACS managed with PCI are
given a prasugrel loading dose of 60 mg no later than an hour
following PCl.11 Patients are then placed on a maintenance
dose of 10 mg daily along with 81-325 mg of aspirin every
day. This maintenance dosage is recommended to continue
for 12 months in patients with UA, NSTEMI and STEM!. However, the clinician may choose to extend treatment duration
to 15 months in UA and NSTEMI patients, unless the risk of
bleeding outweighs the benefits. Prasugrel should not be
given to patients who have active pathological bleeding or a
history of transient ischemic attack or stroke. Furthermore,
due to an increased risk of complications, the maintenance
dose is suggested to be decreased to 5 mg once daily in patients who weigh less than 60 kg. Adverse reactions are rare,
but can be fatal; as may be the case with bleeding. Other cardiovascular adverse reactions occurring in less than 10 per-
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cent of patients include hypertension, hypotension, atrial
fibrillation, bradycardia, hyperlipidemia and epistaxis.
The Prasugrel in Comparison to Clopidogrel for Inhibition of
Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) was a phase II, double-blind, randomized, crossover study comparing prasugrel
and clopidogrel in patients referred for PCf.12 Patients in the
prasugrel group received 60 mg as a loading dose and 10 mg
per day as a maintenance dose while the clopidogrel group
received 600 mg as a loading dose and 150 mg per day as a
maintenance dose. The maintenance dose lasted through the
28-day crossover period, with an inhibition of platelet aggregation (IPA) endpoint measurement after 14 days of either
drug. The primary endpoint after the loading dose phase was
IPA with 20 µmoljL ADP after six hours. The IPA of the prasugrel group was significantly higher than in the clopidogrel
group. The study concluded prasugrel was the preferred
treatment because of the increased platelet inhibition, but
did not address clinical endpoints such as Ml, stroke or CV
death.
Prasugrel versus clopidogrel in patients with acute coronary
syndromes (TRITON-TIMI 38) was a double-blind, randomized controlled trial in 30 countries with 13,608 people
participating.13 Patients in the clopidogrel group received
300 mg as a loading dose and a maintenance dose of 75 mg
per day. Those in the prasugrel group received 60 mg as a
loading dose followed by 10 mg per day as a maintenance
dose. The primary efficacy endpoint was the composite of
death from cardiovascular causes, nonfatal MI and nonfatal
stroke. Overall, there was a significant reduction in the primary efficacy endpoint when using prasugrel as compared to
clopidogrel with a hazard ratio (HR) of 0.81 with a 95 percent confidence interval (95% CI) of 0.73 to 0.90 (P<0.001).
Key secondary endpoints for the follow-up were stent thrombosis and a composite of death due to cardiovascular events,
nonfatal Ml, nonfatal stroke or rehospitalization due to a cardiac ischemic event. The secondary endpoint of stent thrombosis was also significantly reduced (HR 0.48, 95% CI 0.36 to
0.64, P<0.001). The other secondary endpoint of death from
cardiovascular causes, nonfatal Ml, nonfatal stroke or rehospitalization for ischemia was again significantly reduced (HR
0.84, 95% CI 0.76 to 0.92, P<0.001). The study concluded
prasugrel is more effective at reducing thrombotic cardiovascular events than clopidogrel for patients undergoing PC!
with STEM!. However, clinicians should weigh these benefits
against the increased risk of bleeds.
Ticagrelor
What Makes Ticagrelor Different?
On July 20, 2011, the FDA approved ticagrelor to reduce the
rate of thrombotic cardiovascular events in patients with
ACS. 14 This drug is the first in a novel chemical class, the
cyclopentyltriazolapyramides.lSTicagrelor is unique as compared to clopidogrel and prasugrel in that it displays directacting P2Y 12 receptor antagonism, as well as reversible binding
properties. Ticagrelor typically reaches peak levels in 1.5
hours. Also, there is at least one metabolite of ticagrelor that
exhibits the same action as the parent compound.
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The other notable difference between ticagrelor as compared
with clopidogrel and prasugrel is seen in regard to binding
properties. When clopidogrel and prasugrel bind, they are
present throughout the entire life-span of the platelet. If the
patient must discontinue the drug for any reason, most commonly for surgical preparation, it will take approximately
one week for the effect of the drug to disappear.z Ticagrelor,
on the other hand, is reversible, which leads to a quicker offset of action than other platelet-inhibiting therapeutic
agents. The reversibility may prove advantageous for patients who need to have a Coronary Artery Bypass Graft
(CABG). Although the manufacturer recommends a five-day
waiting period before surgery, it could be theorized that ticagrelor could wear off faster than clopidogrel or prasugrel
given the reversible properties of the drug.16
Safety and Efficacy
One of the first studies to evaluate the safety and efficacy of
ticagrelor versus clopidogrel in patients with NSTEMI was
the Safety, Tolerability, and Initial Efficacy of AZD6140, the
First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared with Clopidogrel, in Patients with NonST-Segment Elevation Acute Coronary Syndrome: the DISPERSE-2 Trial. The study compared major and minor bleeding between the groups. The study found no significant difference in major bleeding. However, there was a significant
difference in minor bleeding with ticagrelor having a higher
incidence than clopidogrel. Also, the doses of ticagrelor
yielded a level of platelet inhibition nearly double that of
clopidogrel.17 Furthermore, patients who discontinued ticagrelor one to five days prior to undergoing CABG experienced a lower rate of procedure-related bleeding than patients who had been in the clopidogrel group. This study
paved the way for other studies to take place to analyze the
efficacy of ticagrelor in ACS.

One landmark study was the Study of Platelet Inhibition and
Patient Outcomes (PLATO) that was conducted to determine
whether ticagrelor was superior to clopidogrel for the prevention of vascular events and death.lBPatients were assigned to receive ticagrelor or clopidogrel with aspirin given
to both treatment arms at a dose of 75-100 mg daily, unless
the patient was unable to tolerate it. Ticagrelor was given as
a 180 mg loading dose, followed by 90 mg twice daily. Clopidogrel was given as a 300 mg loading dose for patients who
had not already been taking it, followed by 7 5 mg daily. The
primary endpoint of this study was a composite of deaths
from vascular causes, or any other cause. At the end of one
year, it was discovered that the primary endpoint occurred
less in the ticagrelor group (9.8 percent) than in the clopidogrel group (11.7 percent). The difference in the effect of the
treatment was apparent from day 30 of the study and remained consistent Secondary endpoints evaluated were
death due to individual types of events, such as MI or stroke,
and there was a reduction in deaths from MI individually as
well as vascular events. Additionally, there was a reduction
in the risk of stent thrombosis; however, there were more
deaths from hemorrhagic stroke in the ticagrelor group compared to the clopidogrel group (0.2 percent versus 0.1 perJanuary 2012 Volume 3, Issue 1
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cent, respectively). This study showed there was no benefit
of ticagrelor use in patients weighing less than the median
weight for their sex, taking lipid lowering drugs or living in
North America. There was also a higher rate of nonprocedure related bleeding, as well as a higher rate of dyspnea in patients who received ticagrelor. It should be noted
the risk of dyspnea was relatively low and does not mean the
clear benefits of ticagrelor in regard to prevention of death
should be disregarded. Despite the negative results shown in
patients in North America, the FDA still chose to approve the
drug. Potential considerations include the small sample size
of North American study participants in the PLATO study and
a different aspirin dosing regimen observed in North America.19 Therefore, ticagrelor may still be used in North American patients as long as aspirin doses are maintained below
100 mg daily.
The genetic polymorphisms affecting clopidogrel action in
different patients, specifically the CYP2Cl 9 genotype, do not
impact the effects of ticagrelor.z Therefore, if ticagrelor is
used instead of clopidogrel, it would eliminate the need for
the genetic testing currently recommended by the FDA for
clopidogrel. Another PLATO substudy focused on patients
who were scheduled to receive non-invasive treatment. The
substudy found ticagrelor consistently reduced ischemic
events in ACS patients whether or not they were scheduled
for invasive stent placement or non-invasive treatment, implying that the intensified effects are beneficial in either
management strategy.zo At this time, head-to-head studies
comparing prasugrel and ticagrelor have not been conducted. Therefore, it is difficult to discern if there is greater
benefit shown when using prasugrel vs. ticagrelor.
As clopidogrel nonresponsiveness has become a clinical concern, the Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
(RESPOND) Study set out to determine the feasibility of
switching patients who fail clopidogrel treatment to ticagrelor. Ninety-eight patients were given 300 mg of clopidogrel
and were then assessed for response via light transmittance
aggregometry.4 Once the patient was determined to be a responder or nonresponder to clopidogrel, he was randomly
assigned to receive either clopidogrel 75 mg per day or ticagrelor 90 mg twice a day for two weeks. After two weeks, all
nonresponders switched treatments and half of the responders switched treatments. The patients who tested nonresponsive to clopidogrel were responsive to ticagrelor. The
platelet aggregation of these patients fell from 59 ± 9 percent
to 35 ± 11 percent when switching from clopidogrel to ticagrelor and rose from 36 ± 14 percent to 56 ± 9 percent when
switching from ticagrelor to clopidogrel. Therefore, ticagreIor was determined to be effective in overcoming clopidogrel
nonresponsiveness. In the responder group, platelet aggregation showed statistically significant improvement in patients
treated with ticagrelor. Additionally, it was found patients
were able to switch directly from clopidogrel to ticagrelor
without any reduction in antiplatelet effect. Therefore, ticagrelor is a promising therapeutic option for dealing with patients who experience clopidogrel nonresponsiveness.
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Another trial, a randomized, double-blind assessment of the
ONSET and OFFSET of the antiplatelet effects of ticagrelor
versus clopidogrel in patients with stable coronary artery
disease: the ONSET /OFFSET study, provided further clinical
support for the use of ticagrelor. 21 ONSET /OFFSET was a
study encompassing 123 patients with stable coronary artery
disease who received either 90 mg ticagrelor twice daily, 7 5
mg clopidogrel once daily or placebo for six weeks. Ultimately, greater platelet inhibition occurred with ticagrelor at
all times tested and a faster onset of action was noted. Also,
there was a faster offset of action when the patients were
taken off the drug at the end of week six. The level of platelet
inhibition of ticagrelor after the third day of being taken off
the medication was comparable to day five of the clopidogrel
patients. The faster offset of action could be beneficial if the
patient needed surgery or if they had to discontinue their
antiplatelet medication for any other reason. Despite this
evidence, as mentioned previously, the drug manufacturer
still recommends discontinuing ticagrelor five days prior to
surgery.17
Clinical Considerations
Although ticagrelor shows great promise in the treatment of
ACS, there are several drawbacks to consider. The first is that
ticagrelor has been shown to have an increased risk of fatal
intracranial bleeding and higher rates of GI-related bleeding
as compared to clopidogrel; however, it should be considered that the percentage of intracranial bleeding and GI
bleeds may not outweigh the benefits of improved cardiovascular outcomes.2 Clinicians may want to keep these bleeding
risks in mind and carefully monitor patients at a higher risk
for bleeding if ticagrelor is chosen. Also, dyspnea was noted
at an increase of about 6 percent compared to clopidogrel.
Dyspnea may impact long-term adherence and should be
monitored. Additionally, a slightly greater increase in serum
creatinine and uric acid levels was noted in the PLATO trial,
regarding ticagrelor compared to clopidogrel. Serum uric
acid levels increased with ticagrelor compared to clopidogrel, but reports of gout did not differ between groups.is
Serum creatinine increased in patients taking ticagrelor
compared to clopidogrel. Due to the increase in serum
creatinine, renally impaired patients should be monitored
when either antiplatelet agent is administered. In regard to
other medications, ticagrelor increases levels of drugs
metabolized through CYP3A4, such as simvastatin. CYP3A4
inhibitors, such as diltiazem, increase the levels of ticagrelor
and reduce the speed of offset.22

Ticagrelor prescribing information states that it is recommended for use in all forms of ACS.16Ticagrelor is taken in
conjunction with aspirin, though aspirin doses above 100 mg
have been shown to decrease the effectiveness of the drug.
Treatment starts with a 180 mg loading dose followed by 90
mg twice daily. Aspirin is delivered as a 325 mg loading dose
and then 75-100 mg daily. Ticagrelor is contraindicated in
patients with a history of intracranial hemorrhaging, active
pathological bleeding or severe hepatic impairment.14 Patients may experience dyspnea and may be at a greater risk
for non-procedural related bleeding, easier bruising, longer
bleeding times and an increased likelihood of epistaxis.
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Conclusion
Although clopidogrel has been the standard of care for the
treatment of ACS for several years, the recent approval of
prasugrel and ticagrelor now allows for alternative therapies. Ticagrelor specifically exhibits clinically different pharmacologic characteristics that require twice daily dosing, but
also allows for faster onset and offset, as well as more predictable platelet inhibition as compared to clopidogrel. It is
important to individualize antiplatelet therapy to ensure the
best possible therapeutic outcomes. Additional postmarketing surveillance and treatment guidelines will hopefully continue to guide appropriate selection of antiplatelet therapies.
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Assessment Questions
1. Clopidogrel is not recommended in patients with reduced
_ _ function, due to decreased activation of the drug.
a. CYP2C19
b. Platelet
c. Kidney
d. All of the above
e. Band C
2. Ticagrelor's primary mechanism of action can be described
as:
a. Conversion by liver metabolism to form an active
metabolite that will bind to the P2Y 12 receptor
b. Direct binding to the P2Y12 receptor
c. Conversion by liver metabolism to form an active
metabolite that will bind directly to CYP3A4
d. Direct binding to CYP3A4
3. Due to differences in binding, ticagrelor has a slower onset
of action than clopidogrel.
a. True
b. False
4. The genetic polymorphisms affecting the action of clopidogrel in different patients do not impact the effects of ticagrelor.
a. True
b. False

9. Ticagrelor is contraindicated in patients with:
a. Bradyarrythmia
b. Under 60 kg
c. History of asthma
d. None of the above
10. Which of the following drugs increases the level of other
medications metabolized through CYP3A4?
a. ticagrelor
b. prasugrel
c. clopidogrel
d. All of the above

Ohio Northern University is accredited by the
Accreditation Council for Phannacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 11/29114.

To receive continuing education credit for this program, you
must answer the above questions and fill out the evaluation
form. Please visit www.onu.edu/pharmacy to enter the required information. Please allow two to three weeks for
electronic distribution of your continuing education certificate, which will be sent to your valid email address in PDF
format.

5. BT is a 68-year-old female who is 5'2" and 67 kg. Platelet
function testing shows BT is unresponsive to clopidogrel.
Which of the following is/are appropriate alternative therapy?
a. prasugrel
b. ticagrelor
c. Either A or B
d. None of the above
6. Ticagrelor offers decreased risk of intra cranial bleeding
over clopidogrel.
a. True
b. False
7. Patient compliance due to twice daily dosing may be an
issue with:
a. clopidogrel
b. prasugrel
c. ticagrelor
d. All of the above
8. Adverse effects associated with ticagrelor include:
a. Dyspnea
b. GI bleeding
c. Intracranial bleeds
d. All of the above
e. Aand C
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To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below
including your indicated answers to the assessment questions and return to:

Office of Continuing Education at the Raabe College of Pharmacy
Ohio Northern University
525 South Main Street
Ada, Ohio 45810

The Emerging Role ofTicagrelor in Acute Coronary Syndromes
UAN: 0048-0000-11-051-H01-P CEUs: 0.1

Program Title:

All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of
continuing education credit Certificates will be distributed as a PDF document to a valid email address.

Name:
Address:
City:

State:

Phone:

E-mail:

Pharmacy License #:

State:

Zip:

y

ONU Alumni?

N

1

2

3

4

5

List the disease states associated with acute coronary syndromes and
general treatment approaches.

1

2

3

4

5

Describe the rationale behind the development of new antiplatelet
drug therapies.

1

2

3

4

5

Explain the mechanisms of action of clopidogrel, prasugrel and
ticagrelor.

1

2

3

4

5

List the advantages and disadvantages of treating ACS with either
clopidogrel, prasugrel or ticagrelor.

1

2

3

4

5

Describe the appropriate patient populations indicated for each drug
therapy.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program objectives were clear.
The program met the stated goals and objectives:

Comment/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer

1. A B C D E

4.

A B

7.

A B C D

2.

A B C D

5.

A B C D

8.

A B C D E

3.

A B

6.

A B

9.

A B C D

Any questions/comments regarding this continuing education program can

be directed to Lynn Bedford, Advanced Administrative Assistant for the
Office of Continuing Education (email: l-bedford@onu.edu, phone 419772-1871).

~-

10. A B C D

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 11/29/14.

